Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New triple therapy aims to shrink stomach tumors before surgery

NCT ID NCT07165847

First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 33 times

Summary

This study tests whether adding radiation to a mix of chemotherapy and two immunotherapy drugs before surgery can improve outcomes for people with resectable stomach or gastroesophageal junction cancer. About 40 adults with HER2-negative disease will be randomly assigned to receive either the standard chemo-immunotherapy or the same plus radiation. The main goal is to see how many patients have no cancer cells left in the removed tissue (pathological complete response).

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC CANCER (GC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Army Medical Center

    RECRUITING

    Chongqing, Other (Non U.s.), 400000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.